Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Identifying Opportunity, Placing Risk -- Analyst Notes on Cara Therapeutics, Sigma Designs, Pep Boys - Manny Moe and Jack and Nektar Therapeutics

Accesswire December 21, 2015

Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age

Business Wire December 21, 2015

A Change in Tides - Complementary Research on Nektar, California Resources, Zynga and Finisar

Accesswire December 10, 2015

Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York

PR Newswire December 8, 2015

Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

PR Newswire December 8, 2015

Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London

PR Newswire November 17, 2015

Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds

PR Newswire November 16, 2015

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015

PR Newswire November 5, 2015

Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets

PR Newswire October 29, 2015

Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day

PR Newswire October 8, 2015

Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

PR Newswire October 7, 2015

Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020

PR Newswire October 6, 2015

Nektar to Host Research & Development Day for Analysts and Investors on October 8th

PR Newswire October 1, 2015

Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models

PR Newswire September 21, 2015

Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

PR Newswire September 1, 2015

R. Scott Greer Joins Inogen Board of Directors

GlobeNewswire August 6, 2015

R. Scott Greer Joins Inogen Board of Directors

GlobeNewswire August 6, 2015

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015

PR Newswire August 5, 2015

Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets

PR Newswire July 29, 2015

Columbia Pipeline to Join the S&P 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600

PR Newswire June 24, 2015